DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

AstraZeneca Pharma India Limited Valuation

ASTRAZEN · Healthcare · Current price ₹5,932

Full stock page

DocStoX fair value

Not published yet

No estimate for ASTRAZEN at this time

Current price

₹5,932

P/E ratio

79.1x

P/B ratio

19.6x

Model it yourself — Earnings Yield Calculator

Opens pre-filled with AstraZeneca Pharma India Limited's latest numbers.

Is AstraZeneca Pharma India Limited undervalued?

We have not published a fair value estimate for AstraZeneca Pharma India Limited yet. Our valuation engine covers the market in waves, and this company has not been through a run that met our publishing bar. Rather than show a second, inconsistent number here, we would rather show none. The ratios, peer comparison and methodology below are still based on AstraZeneca Pharma India Limited's reported financials.

Valuation multiples

AstraZeneca Pharma India Limited trades at a P/E of 79.1x and a P/B of 19.6x, with a dividend yield of 0.5%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.

How we estimate fair value

When we publish an estimate for AstraZeneca Pharma India Limited, it will appear here with the full working: the models used and their weights, every assumption and its source, the confidence band, and what data was missing. That is the same methodology we apply to every company.

Read the full fair-value methodology

Understand the ratios

P/E Ratio P/B Ratio PEG Ratio Earnings Yield

More on AstraZeneca Pharma India Limited

Fair Value Intrinsic Value DCF Financial Ratios Peers

DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.